Fotivda (Tivozanib HCl) Patent Expiration, LOE Window & CMS Spending
Fotivda (Tivozanib HCl) by Aveo: FDA Orange Book core substance LOE 2028-11-16 (last listed 2039-11-05), 0 AB generics, $126.1M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Aveo |
| FDA Application & Pathway | N212904 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2028-11-16 |
| Last Listed Patent or Exclusivity Date | 2039-11-05 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $126.1M |
| 2024 Medicare Part D Spend | $118.9M |
| 2024 Medicaid Spend | $7.2M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 25.4% 2-yr change) |